“…Residual pulmonary damage could also contribute to the development to new clinical disorders (such as cardiac disorders, hypertension, diabetes, and renal disorders) as well as the worsening of pre-existing clinical disorders among individuals with COVID-19 compared to those of matched controls [ 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ], which has broad health implications. Thoracic imaging, such a computed tomography (CT), can be used to evaluate the residual pulmonary effects from COVID-19 and provide valuable insights into the long-term morphological changes in the respiratory system, with ground-glass opacities (GGO), consolidations, and fibrosis being characteristic features frequently identified in the chest imaging of individuals with acute COVID-19 [ 8 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 ]. Emerging evidence suggests that the above-mentioned lingering respiratory symptoms are often accompanied by distinct CT findings, providing a visual narrative of the protracted aftermath of SARS-CoV-2 infection.…”